MID for analyzing the cost-effectiveness of two therapies for HIV:

- monotherapy, which means "only zidovudine".

- combined therapy, which means "zidovudine plus lamivudine for the first three years (i.e., three cycles), then zidovudine alone".

Original paper:

Chancellor JV, et al.

Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infection.

Pharmacoeconomics 1997;12:54-66.

An MS Excel version of this model was included as an exercise in:

Briggs A, Claxton K, Sculpher M.

Decision Modelling for Health Economic Evaluation.

Oxford University Press, 2006

www.herc.ox.ac.uk/downloads/supporting-material-for-decision-modelling-for-health-economic-evaluation, exercise 4.7, or

https://www.herc.ox.ac.uk/downloads/supporting-material-for-decision-modelling-for-health-economic-evaluation/ex47sol.xls.

MID built by Iñigo Bermejo and F. Javier Díez in July 2013.

Revised: 20 January 2015.

The discounts, taken from the Excel file, are 6% por costs and 0% for effectiveness. Open the properties dialog of each node to obtain additional information. See also the chapter on MIDs in OpenMarkov's tutorial.

]]>

Health state of the VIH patient: State A (200<cd4 cells/mm3<500); State B (cd4<200); State C (AIDs); Death

]]> 1.0 1.0 0.01 0.01 0.01 0.01 0.01 0.0 0.0 0.0 1.0 This transition probability does not allow patients to recover to a less severe state: they can only remain in the same state or get worse. If the therapy chosen is combination therapy, this is applied in the first three cycles--0, 1, and 2--but then monotherapy is applied in all cases. ]]> 1.0 0.0 0.0 0.0 0.2498570612 0.7501429388 0.0 0.0 0.0119236884 0.4069952305 0.5810810811 0.0 0.0098039216 0.0668973472 0.2018454441 0.7214532872 1.0 0.0 0.0 0.0 0.1271772441 0.8728227559 0.0 0.0 0.0060691574 0.2071605723 0.7867702703 0.0 0.0049901961 0.0340507497 0.102739331 0.8582197232 monotherapy 0.0 2085.50445 0.0 0.0 0.0 1.0 0.0 0.0 6948.0 1774.0 1701.0 0.0 2059.0 1278.0 1055.0 2278.0 0.0 COST_EFFECTIVENESS £ 20 BEGINNING